title: Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.
abstract: About 50% of patients with breast cancer have no involvement of axillary lymph nodes at diagnosis and can be considered cured after primary locoregional treatment. However, about 20-30% will experience distant relapse. The group of patients at risk is not well characterised: recurrence is probably due to the establishment of micrometastases before treatment. Given the early steps of metastasis in which tumour cells interact with endothelial cells of blood vessels, and, given the independent prognostic value in breast cancer of both the quantification of tumour vascularisation and the detection of micrometastases in the bone marrow, the aim of this study was to determine the relationship between vascularisation, measured by Chalkley morphometry, and the bone marrow content of cytokeratin-19 (CK-19) mRNA, quantified by real-time reverse transcriptase polymerase chain reaction, in a series of 68 patients with localised untreated breast cancer. The blood concentration of factors involved in angiogenesis (interleukin-6 and vascular endothelial growth factor) and of factors involved in coagulation (D-dimer, fibrinogen, platelets) was also measured. When bone marrow CK-19 relative gene expression (RGE) was categorised according to the cut-off value of 0.77 (95th centile of control patients), 53% of the patients had an elevated CK-19 RGE. Patients with bone marrow micrometastases, on the basis of an elevated CK-19 RGE, had a mean Chalkley count of 7.5 +/- 1.7 (median 7, standard error [SE] 0.30) compared with a mean Chalkley count of 6.5 +/- 1.7 in other patients (median 6, SE 0.3) (Mann-Whitney U-test; P = 0.04). Multiple regression analysis revealed that Chalkley count, not lymph node status, independently predicted CK-19 RGE status (P = 0.04; odds ratio 1.38; 95% confidence interval 1.009-1.882). Blood parameters reflecting angiogenesis and coagulation were positively correlated with Chalkley count and/or CK-19 RGE. Our data are in support of an association between elevated relative microvessel area of the primary tumour and the presence of bone marrow micrometastases in breast cancer patients with operable disease, and corroborate the paracrine and endocrine role of interleukin-6 and the involvement of coagulation in breast cancer growth and metastasis.
authors.affiliation: Translational Cancer Research Group Antwerp, Laboratory of Pathology, University of Antwerp/University Hospital Antwerp, Edegem, Belgium. ina.benoy@pandora.be <ina.benoy@pandora.be>
authors.forename: Ina H
authors.initials: IH
authors.lastname: Benoy
authors.forename: Roberto
authors.initials: R
authors.lastname: Salgado
authors.forename: Hilde
authors.initials: H
authors.lastname: Elst
authors.forename: Peter
authors.initials: P
authors.lastname: Van Dam
authors.forename: Joost
authors.initials: J
authors.lastname: Weyler
authors.forename: Eric
authors.initials: E
authors.lastname: Van Marck
authors.forename: Simon
authors.initials: S
authors.lastname: Scharpé
authors.forename: Peter B
authors.initials: PB
authors.lastname: Vermeulen
authors.forename: Luc Y
authors.initials: LY
authors.lastname: Dirix
mesh_terms: D000368:Aged; D019046:Bone Marrow Neoplasms / Q000556:secondary*; D001943:Breast Neoplasms / Q000098:blood supply* / Q000473:pathology*; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006133:Growth Substances / Q000097:blood; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology; D007633:Keratins / Q000032:analysis / Q000235:genetics*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000503:physiopathology*; D009389:Neovascularization, Pathologic; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D012044:Regression Analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity
chemical_list: D016207:Cytokines; D006133:Growth Substances; D015850:Interleukin-6; D012333:RNA, Messenger; D007633:Keratins
references.citation: Clin Cancer Res. 2000 Jan;6(1):139-46
references.pmid: 10656442
references.citation: Nat Med. 1999 Apr;5(4):434-8
references.pmid: 10202935
references.citation: Nat Med. 2000 Apr;6(4):389-95
references.pmid: 10742145
references.citation: Ann N Y Acad Sci. 2000 May;902:249-62; discussion 262-4
references.pmid: 10865845
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: J Pathol. 2001 Oct;195(3):336-42
references.pmid: 11673831
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Br J Cancer. 2002 Feb 1;86(3):389-95
references.pmid: 11875705
references.citation: Histopathology. 2001 Dec;39(6):551-3
references.pmid: 11903570
references.citation: Eur J Cancer. 2002 Aug;38(12):1564-79
references.pmid: 12142044
references.citation: Lancet. 2002 Aug 31;360(9334):683-9
references.pmid: 12241875
references.citation: Br J Cancer. 2002 Dec 2;87(12):1437-44
references.pmid: 12454774
references.citation: Int J Cancer. 2003 Feb 20;103(5):642-6
references.pmid: 12494472
references.citation: Br J Surg. 2003 Mar;90(3):290-301
references.pmid: 12594663
references.citation: Br J Cancer. 2003 Mar 10;88(5):718-25
references.pmid: 12618881
references.citation: Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9
references.pmid: 12714683
references.citation: Histopathology. 2003 Jun;42(6):530-40
references.pmid: 12786888
references.citation: J Clin Oncol. 2003 Jul 1;21(13):2609-15
references.pmid: 12829682
references.citation: Cell. 2003 Jun 27;113(7):821-3
references.pmid: 12837240
references.citation: Cancer Res. 2003 Sep 15;63(18):5679-84
references.pmid: 14522883
references.citation: Int J Cancer. 2004 Feb 10;108(4):620-7
references.pmid: 14696130
references.citation: Cancer Res. 2004 May 1;64(9):2941-55
references.pmid: 15126324
references.citation: N Engl J Med. 1986 Dec 25;315(26):1650-9
references.pmid: 3537791
references.citation: Cancer. 1989 Jan 1;63(1):181-7
references.pmid: 2910416
references.citation: N Engl J Med. 1991 Jan 3;324(1):1-8
references.pmid: 1701519
references.citation: J Clin Oncol. 1991 Oct;9(10):1749-56
references.pmid: 1919627
references.citation: J Cell Physiol. 1994 May;159(2):245-55
references.pmid: 8163565
references.citation: Am J Pathol. 1998 Feb;152(2):399-411
references.pmid: 9466566
references.citation: Br J Cancer. 1999 May;80(5-6):892-7
references.pmid: 10360671
references.citation: Br J Cancer. 2004 Nov 15;91(10):1813-20
references.pmid: 15505629
references.citation: Lancet. 1995 Nov 18;346(8986):1334-5
references.pmid: 7475773
references.citation: Br J Cancer. 1996 Jan;73(1):79-82
references.pmid: 8554988
references.citation: J Natl Cancer Inst. 1997 Jul 16;89(14):1044-9
references.pmid: 9230886
references.citation: Am J Pathol. 1997 Nov;151(5):1417-23
references.pmid: 9358768
references.citation: Nat Med. 1998 Aug;4(8):923-8
references.pmid: 9701244
references.citation: N Engl J Med. 2000 Feb 24;342(8):525-33
references.pmid: 10684910